Table 1 Patient characteristics
From: Long-term clinical outcomes of patients with nonsignificant transplanted renal artery stenosis
N | 54 |
Age (years) (mean (SD)) | 35.93 (15.96) |
Sex (%, women) | 10 (18.5) |
Whites (%) | 22 (40.7) |
Weight (kg, D0) (mean (SD)) | 64.61 (18.32) |
Height (cm, D0) (mean (SD)) | 168.50 (11.39) |
BMI (kg/m2) (mean (SD)) | 22.39 (4.83) |
Time on dialysis (months) (mean (SD)) | 33.10 (25.88) |
Type of dialysis (%) | |
Haemodialysis | 49 (96.1) |
Peritoneal dialysis | 1 (2.0) |
Conservative treatment | 1 (2.0) |
HLA class (%) | |
Ident (I) | 27 (54.0) |
Hapto (II) | 6 (12.0) |
Dist (III) | 6 (12.0) |
CAD | 11 (22.0) |
Hypertension (%) | 43 (79.6) |
Diabetes mellitus (%) | 15 (27.8) |
Dyslipidaemia (%) | 5 (9.3) |
Smoking (%) | 3 (5.6) |
EBV serum (% positive) | 5 (13.9) |
CMV serum (% positive) | 47 (90.4) |
CMV prophylaxis (%) | 17 (32.1) |
Prior hypertensive nephropathy (%) | 9 (16.7) |
Prior diabetic nephropathy (%) | 12 (22.2) |
Prior polycystic nephropathy (%) | 3 (5.6) |
Prior glomerulonephritis (%) | 10 (18.5) |
Prior other diagnoses (%) | 6 (11.1) |
Prior unknown cause of CKD (%) | 19 (35.2) |
Other diseases (%) | |
NA | 49 (90.7) |
Indeterminate | 1 (1.9) |
Repeated urinary infection | 1 (1.9) |
Renal malformation | 1 (1.9) |
Repeating pyelonephritis | 1 (1.9) |
Posterior urethral valve | 1 (1.9) |
Alive donor (%) | 18 (33.3) |
Deceased donor (%) | 36 (66.7) |
Panel (%) (mean (SD)) | 7.23 (18.69) |
Second transplantation (index Tx) | 1 (1.9) |
Time since transplantation (months) (median [IQR]) | 5.00 [3.00, 9.00] |
TAV (median [IQR]) | 30.00 [25.00, 37.00] |
TIF (mean (SD)) | 17.67 (12.14) |
Total cholesterol (mg/dL) (mean (SD)) | 170.93 (46.93) |
HDL-C (mg/dL) (mean (SD)) | 43.85 (11.50) |
LDL-C (mg/dL) (mean (SD)) | 106.45 (46.22) |
Cause of death (donor) (%) | |
NA | 19 (35.2) |
CV disease | 5 (9.3) |
Neurologic disease | 17 (31.5) |
Trauma | 13 (24.1) |
Type of graft (%) | |
NA | 14 (25.9) |
Gregoir | 32 (59.3) |
Politano | 4 (7.4) |
Ureteropielo | 4 (7.4) |
Blood type (%) | |
NA | 7 (13.0) |
A | 15 (27.8) |
AB | 3 (5.6) |
B | 7 (13.0) |
O | 22 (40.7) |
RH factor = + (%) (n = 16) | 16 (100.0) |
Blood transfusion | 17 (33.3) |
Baseline Meds | |
Anti-hypertensive meds at baseline (%) | 43 (100.0) |
ACEi at baseline (%) | 17 (31.5) |
ARB at baseline (%) | 6 (11.1) |
Beta-blocker at baseline (%) | 21 (38.9) |
Diuretic at baseline (%) | 10 (18.5) |
Vasodilator at baseline (%) | 14 (25.9) |
Calcium channel blockers at baseline (%) | 25 (46.3) |
Central alpha-antagonist at baseline (%) | 5 (9.3) |
Insulin at baseline (%) | 10 (18.5) |
Oral hypoglycaemic meds at baseline (%) | 5 (9.3) |
Hypolipidaemic meds at baseline (%) | 3 (5.6) |
Simvastatin at baseline (%) | 2 (3.7) |
Atorvastatin at baseline (%) | 0 (0) |
Rosuvastatin at baseline (%) | 0 (0) |
Post-Tx smoking | 2 (3.9) |
Treatment for rejection | 18 (34.6) |
ISS tacrolimus | 36 (70.6) |
ISS mycophenolate | 18 (35.3) |
ISS prednisone | 50 (98.0) |
ISS cyclosporine | 15 (29.4) |
ISS azathioprine | 34 (66.7) |